{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T20:53:39Z","timestamp":1761598419449,"version":"build-2065373602"},"reference-count":39,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2022,3,8]],"date-time":"2022-03-08T00:00:00Z","timestamp":1646697600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","award":["BCM-UPS, grant #682473"],"award-info":[{"award-number":["BCM-UPS, grant #682473"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SFB 1335"],"award-info":[{"award-number":["SFB 1335"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Diffuse large B cell lymphomas (DLBCL) are the most common neoplasia of the lymphatic system. Circulating cell-free DNA released from tumor cells (ctDNA) has been studied in many tumor entities and successfully used to monitor treatment and follow up. Studies of ctDNA in DLBCL so far have mainly focused on tracking mutations in peripheral blood initially detected by next-generation sequencing (NGS) of tumor tissue from one lymphoma manifestation site. This approach, however, cannot capture the mutational heterogeneity of different tumor sites in its entirety. In this case report, we present repetitive targeted next-generation sequencing combined with digital PCR out of peripheral blood of a patient with DLBCL relapse. By combining both detection methods, we were able to detect a new dominant clone of ctDNA correlating with the development of secondary therapy-related acute myeloid leukemia (t-AML) during the course of observation. Conclusively, our case report reinforces the diagnostic importance of ctDNA in DLBCL as well as the importance of repeated ctDNA sequencing combined with focused digital PCR assays to display the dynamic mutational landscape during the clinical course.<\/jats:p>","DOI":"10.3390\/cancers14061371","type":"journal-article","created":{"date-parts":[[2022,3,8]],"date-time":"2022-03-08T12:35:37Z","timestamp":1646742937000},"page":"1371","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Circulating Tumor DNA Profiling of a Diffuse Large B Cell Lymphoma Patient with Secondary Acute Myeloid Leukemia"],"prefix":"10.3390","volume":"14","author":[{"given":"Irina A.","family":"Kerle","sequence":"first","affiliation":[{"name":"Department of Medicine III, Klinikum Rechts der Isar, School of Medicine, Technical University of Munich, 81675 Munich, Germany"},{"name":"Center for Personalized Oncology, National Center for Tumor Diseases (NCT) Dresden and University Hospital Carl Gustav Carus Dresden at TU Dresden, 01307 Dresden, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ludwig","family":"J\u00e4gerhuber","sequence":"additional","affiliation":[{"name":"Institute of Clinical Chemistry and Pathobiochemistry, Klinikum Rechts der Isar, School of Medicine, Technical University of Munich, 81675 Munich, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramona","family":"Secci","sequence":"additional","affiliation":[{"name":"Institute of Clinical Chemistry and Pathobiochemistry, Klinikum Rechts der Isar, School of Medicine, Technical University of Munich, 81675 Munich, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Pfarr","sequence":"additional","affiliation":[{"name":"Institute of Pathology, School of Medicine, Technical University of Munich, 81675 Munich, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philipp","family":"Bl\u00fcm","sequence":"additional","affiliation":[{"name":"Department of Medicine III, Klinikum Rechts der Isar, School of Medicine, Technical University of Munich, 81675 Munich, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7684-7986","authenticated-orcid":false,"given":"Romina","family":"Roesch","sequence":"additional","affiliation":[{"name":"Institute of Clinical Chemistry and Pathobiochemistry, Klinikum Rechts der Isar, School of Medicine, Technical University of Munich, 81675 Munich, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6276-8002","authenticated-orcid":false,"given":"Katharina S.","family":"G\u00f6tze","sequence":"additional","affiliation":[{"name":"Department of Medicine III, Klinikum Rechts der Isar, School of Medicine, Technical University of Munich, 81675 Munich, Germany"},{"name":"German Cancer Consortium (DKTK), Partner Site Munich, 81675 Munich, Germany"},{"name":"German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wilko","family":"Weichert","sequence":"additional","affiliation":[{"name":"Institute of Pathology, School of Medicine, Technical University of Munich, 81675 Munich, Germany"},{"name":"German Cancer Consortium (DKTK), Partner Site Munich, 81675 Munich, Germany"},{"name":"German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Bassermann","sequence":"additional","affiliation":[{"name":"Department of Medicine III, Klinikum Rechts der Isar, School of Medicine, Technical University of Munich, 81675 Munich, Germany"},{"name":"German Cancer Consortium (DKTK), Partner Site Munich, 81675 Munich, Germany"},{"name":"German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany"},{"name":"TranslaTUM, Center for Translational Cancer Research, Technical University of Munich, 81675 Munich, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00fcrgen","family":"Ruland","sequence":"additional","affiliation":[{"name":"Institute of Clinical Chemistry and Pathobiochemistry, Klinikum Rechts der Isar, School of Medicine, Technical University of Munich, 81675 Munich, Germany"},{"name":"German Cancer Consortium (DKTK), Partner Site Munich, 81675 Munich, Germany"},{"name":"German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany"},{"name":"TranslaTUM, Center for Translational Cancer Research, Technical University of Munich, 81675 Munich, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0253-9056","authenticated-orcid":false,"given":"Christof","family":"Winter","sequence":"additional","affiliation":[{"name":"Institute of Clinical Chemistry and Pathobiochemistry, Klinikum Rechts der Isar, School of Medicine, Technical University of Munich, 81675 Munich, Germany"},{"name":"German Cancer Consortium (DKTK), Partner Site Munich, 81675 Munich, Germany"},{"name":"German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany"},{"name":"TranslaTUM, Center for Translational Cancer Research, Technical University of Munich, 81675 Munich, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,3,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/00001622-200109000-00003","article-title":"Diffuse large cell lymphoma","volume":"13","author":"Coiffier","year":"2001","journal-title":"Curr. Opin. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1093\/jnci\/92.15.1240","article-title":"Cancer surveillance series: Non-Hodgkin\u2019s lymphoma incidence by histologic subtype in the United States from 1978 through 1995","volume":"92","author":"Groves","year":"2000","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"3724","DOI":"10.1182\/blood-2010-05-282632","article-title":"Incidence of hematologic malignancies in Europe by morphologic subtype: Results of the HAEMACARE project","volume":"116","author":"Sant","year":"2010","journal-title":"Blood"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1200\/JCO.2013.53.5229","article-title":"Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group","volume":"32","author":"Barrington","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"v116","DOI":"10.1093\/annonc\/mdv304","article-title":"Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Tilly","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1053\/j.seminoncol.2008.04.012","article-title":"Therapy-Related Myeloid Leukemia","volume":"35","author":"Godley","year":"2008","journal-title":"Semin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/bjh.14638","article-title":"Subsequent primary malignancies after diffuse large B-cell lymphoma in the modern treatment era","volume":"178","author":"Tao","year":"2017","journal-title":"Br. J. Haematol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"4935","DOI":"10.1200\/JCO.2010.29.1112","article-title":"Second malignancy risks after non-Hodgkin\u2019s lymphoma and chronic lymphocytic leukemia: Differences by lymphoma subtype","volume":"28","author":"Morton","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2012.45.2011","article-title":"Liquid biopsies: Genotyping circulating tumor DNA","volume":"32","author":"Diaz","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"323","DOI":"10.7150\/jca.27615","article-title":"Mutation Profiling of Malignant Lymphoma by Next-Generation Sequencing of Circulating Cell-Free DNA","volume":"10","author":"Sun","year":"2019","journal-title":"J. Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/nrc.2017.7","article-title":"Liquid biopsies come of age: Towards implementation of circulating tumour DNA","volume":"17","author":"Wan","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1080\/14737159.2017.1319765","article-title":"The value of liquid biopsy in diagnosis and monitoring of diffuse large b-cell lymphoma: Recent developments and future potential","volume":"17","author":"Camus","year":"2017","journal-title":"Expert Rev. Mol. Diagn."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1093\/annonc\/mdp006","article-title":"Cell-free circulating DNA in Hodgkin\u2019s and non-Hodgkin\u2019s lymphomas","volume":"20","author":"Hohaus","year":"2009","journal-title":"Ann. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3679","DOI":"10.1182\/blood-2015-03-635169","article-title":"Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing","volume":"125","author":"Kurtz","year":"2015","journal-title":"Blood"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/cdd.2017.180","article-title":"Why are there hotspot mutations in the TP53 gene in human cancers?","volume":"25","author":"Baugh","year":"2017","journal-title":"Cell Death Differ."},{"key":"ref_16","unstructured":"Horak, P., Griffith, M., Danos, A.M., Pitel, B.A., Madhavan, S., Liu, X., Chow, C., Williams, H., Carmody, L., and Barrow-Laing, L. (2022). Standards for the classification of pathogenicity of somatic variants in cancer (oncogenicity): Joint recommendations of Clinical Genome Resource (ClinGen), Cancer Genomics Consortium (CGC), and Variant Interpretation for Cancer Consortium (VICC). Genet. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1200\/JCO.21.02014","article-title":"TP53 Gain-of-Function and Non-Gain-of-Function Mutations Are Differentially Associated With Sidedness-Dependent Prognosis in Metastatic Colorectal Cancer","volume":"40","author":"Pan","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e04439","DOI":"10.1016\/j.heliyon.2020.e04439","article-title":"Detection of somatic TP53 mutation in surgically resected small-cell lung cancer by targeted exome sequencing: Association with longer relapse-free survival","volume":"6","author":"Yokouchi","year":"2020","journal-title":"Heliyon"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.tranon.2016.01.007","article-title":"Genomic Alterations in Biliary Tract Cancer Using Targeted Sequencing","volume":"9","author":"Yoo","year":"2016","journal-title":"Transl. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1182\/bloodadvances.2020001696","article-title":"Genetic and evolutionary patterns of treatment resistance in relapsed B-cell lymphoma","volume":"4","author":"Rushton","year":"2020","journal-title":"Blood Adv."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S1470-2045(15)70106-3","article-title":"Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: A correlative biomarker study","volume":"16","author":"Roschewski","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"364ra155","DOI":"10.1126\/scitranslmed.aai8545","article-title":"Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA","volume":"8","author":"Scherer","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"D941","DOI":"10.1093\/nar\/gky1015","article-title":"COSMIC: The Catalogue of Somatic Mutations in Cancer","volume":"47","author":"Tate","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/j.1365-2141.2004.05324.x","article-title":"Development of a human acute myeloid leukaemia screening panel and consequent identification of novel gene mutation in FLT3 and CCND3","volume":"128","author":"Smith","year":"2005","journal-title":"Br. J. Haematol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1159\/000351054","article-title":"Acute promyelocytic leukemia with Flt3-TKD and WT1 mutations relapsing in a testicle and followed by systemic relapse","volume":"130","author":"Zou","year":"2013","journal-title":"Acta Haematol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/s41467-018-08263-x","article-title":"Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms","volume":"10","author":"Zhang","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3236","DOI":"10.1182\/blood-2014-10-605808","article-title":"Secondary mutations as mediators of resistance to targeted therapy in leukemia","volume":"125","author":"Daver","year":"2015","journal-title":"Blood"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.biopha.2011.04.006","article-title":"Therapy-related myelodysplastic syndrome and acute myeloid leukemia in patients with chronic lymphocytic leukemia treated with fludarabine and cyclophosphamide","volume":"65","author":"Tomin","year":"2011","journal-title":"Biomed. Pharmacother."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"273","DOI":"10.3816\/CBC.2003.n.032","article-title":"Risk for the development of treatment-related acute myelocytic leukemia and myelodysplastic syndrome among patients with breast cancer: Review of the literature and the National Surgical Adjuvant Breast and Bowel Project experience","volume":"4","author":"Smith","year":"2003","journal-title":"Clin. Breast Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1002\/(SICI)1096-911X(199708)29:2<132::AID-MPO11>3.0.CO;2-H","article-title":"Therapy-related acute myeloid leukemia with t(8;21) in a child with previous Ewing\u2019s sarcoma","volume":"29","author":"Lesesve","year":"1997","journal-title":"Med. Pediatric Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1001\/jamaoncol.2018.5625","article-title":"Association of Chemotherapy for Solid Tumors with Development of Therapy-Related Myelodysplastic Syndrome or Acute Myeloid Leukemia in the Modern Era","volume":"5","author":"Morton","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1002\/cncr.31914","article-title":"Myelodysplastic syndrome and acute myeloid leukemia after receipt of granulocyte colony-stimulating factors in older patients with non-Hodgkin lymphoma","volume":"125","author":"Calip","year":"2018","journal-title":"Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s10549-015-3590-1","article-title":"Myelodysplastic syndrome and acute myeloid leukemia following adjuvant chemotherapy with and without granulocyte colony-stimulating factors for breast cancer","volume":"154","author":"Calip","year":"2015","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/S0140-6736(95)92450-7","article-title":"Haematological study of healthy volunteers 5 years after G-CSF","volume":"346","author":"Sakamaki","year":"1995","journal-title":"Lancet"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1159\/000354196","article-title":"G-CSF in Healthy Allogeneic Stem Cell Donors","volume":"40","year":"2013","journal-title":"Transfus. Med. Hemother."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/sj.bmt.1705722","article-title":"Granulocyte-colony stimulating factor administration to healthy individuals and persons with chronic neutropenia or cancer: An overview of safety considerations from the Research on Adverse Drug Events and Reports project","volume":"40","author":"Tigue","year":"2007","journal-title":"Bone Marrow Transplant."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"4930","DOI":"10.1073\/pnas.0401162101","article-title":"A global suppressor motif for p53 cancer mutants","volume":"101","author":"Baroni","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"5562","DOI":"10.1158\/1078-0432.CCR-18-0573","article-title":"T-cell Responses to TP53 \u201cHotspot\u201d Mutations and Unique Neoantigens Expressed by Human Ovarian Cancers","volume":"24","author":"Deniger","year":"2018","journal-title":"Clin. Cancer Res."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/6\/1371\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:33:58Z","timestamp":1760135638000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/6\/1371"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,8]]},"references-count":39,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,3]]}},"alternative-id":["cancers14061371"],"URL":"https:\/\/doi.org\/10.3390\/cancers14061371","relation":{},"ISSN":["2072-6694"],"issn-type":[{"type":"electronic","value":"2072-6694"}],"subject":[],"published":{"date-parts":[[2022,3,8]]}}}